@article{Agrawal_Saha_Mohapatra_2017, title={A rare case of imatinib mesylate induced acute kidney injury}, volume={5}, url={https://www.ijbcp.com/index.php/ijbcp/article/view/572}, DOI={10.18203/2319-2003.ijbcp20162491}, abstractNote={<p>Imatinib is a revolutionary targeted molecule strikingly successful in chronic phase of chronic myeloid leukemia and higher doses are beneficial in the accelerated phase of the disease. It’s known adverse effects include abdominal pain, vomiting, fluid retention, periorbital edema, pleural effusion, myalgia, liver damage and congestive heart failure. Renal damage due to this drug has not been well reported. In this case, the patient developed acute kidney injury as evidenced by raised creatinine level after two months of administration of imatinib mesylate. At 4<sup>th</sup> visit, the levels of urea and creatinine were significantly above the upper normal limit. The patient was kept under supervision of his renal status and at the starting of 5<sup>th</sup> visit decision was made to change the drug from imatinib to nilotinib. Currently the patient is tolerating nilotinib well. Causality assessment using WHO scale revealed imatinib to have possibly caused this rare adverse reaction.</p>}, number={4}, journal={International Journal of Basic & Clinical Pharmacology}, author={Agrawal, Ratna and Saha, Kaustav and Mohapatra, Sabita}, year={2017}, month={Jan.}, pages={1678–1680} }